Implementation of GST is expected to increase the gross domestic product of the country.
Alkem Labs was issued drug alerts twice last year -- in June and July -- for its drug Glimekem.
The draft bill allows euthanasia for patients who can take informed decisions; doctors to be protected from liability.
Daiichi alleged that Singh brothers had concealed and misrepresented critical information concerning US Food and Drug Administration and Department of Justice investigations into Ranbaxy
In 2014, Sun Pharma agreed to buy Ranbaxy -- which was then controlled by Daiichi.
Lavasa will replace Rajan Watal, who retires on Saturday, even as the budgetary process is yet to be finally completed.
NHAI to pull plug on Rs 3,000-crore ventures for poor show
Sanjeev Vashishta, chief executive officer at SRL Diagnostics, talks to Deepak Patel about expansion plans and regulations for the sector.
The Art of Living Foundation chose to hold the World Culture Festival on the Yamuna floodplains in spite of being aware of the environmental, legal consequences, letters exchanged between it and the Delhi Development Authority show.
Govt bans brands with annual sales worth Rs 3,728 crore.
Between 2011 and 2014, they indirectly determined the price of tyres in the market, says report
Lobby group tells USTR it has got assurance from India on compulsory licensing.
A dialysis machine contributes only 6 per cent to the overall cost.
Governing council to meet on Friday to decide his fate afresh
11 states were assessed for access to clean water, energy and sanitation and use of iodised salt.
Experts are betting big on the clause that talks of capital gains.
The impact from NELM on the Indian pharmaceutical sector is estimated to be around Rs 6,000 crore.
'The role reversal of those in favour of GST and those opposing it is troubling.'
The French drug maker has its vaccine approved in Mexico for all four serotypes for patients aged 9 to 45.
The BSE fined 370 listed companies following the Sebi notification.
© 2026 Rediff.com - Investor Information - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances